Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: June 9, 2016
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics
This filing details a private placement financing event rather than operational financial results. Key metrics include:
- Total Capital Raised (Notes): $1,187,000 aggregate principal amount (combining June 3 and June 9 closings).
- Interest Rate: 11% on Unsecured Promissory Notes.
- Warrants Issued: 2,374,000 total warrants to purchase common stock.
- Warrant Exercise Price: $0.30 per share.
- Warrant Term: Five years.
Material Changes
The filing reports a second closing of a Note and Warrant Purchase Agreement initiated on June 3, 2016.
- June 9, 2016 Closing: Issued an additional $380,000 in Notes and warrants for 720,000 shares.
- Cumulative Total: Combined with the initial June 3 closing ($807,000 in Notes and 1,614,000 warrants), the total issuance reached $1,187,000 in Notes and 2,374,000 warrants.
- Terms: The instruments issued on June 9 have identical terms to those issued on June 3.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the completion of a private placement under Section 4(2) of the Securities Act of 1933 and Regulation D. No forward-looking guidance or operational outlook is provided in this specific report.
Risks and Contingencies: The filing notes that the descriptions of the Notes and Warrants are not complete and are qualified by reference to the full text of the documents filed as Exhibits 4.1, 4.2, and 10.1. The creation of a direct financial obligation is noted under Item 2.03.
Investor Verification Checklist
- Verify the full terms of the 11% Unsecured Promissory Notes in Exhibit 4.1.
- Review the specific rights and obligations regarding the Common Stock Purchase Warrants in Exhibit 4.2.
- Examine the complete Note and Warrant Purchase Agreement in Exhibit 10.1 for covenants and default conditions.
- Confirm the total dilution impact of 2,374,000 potential new shares at the $0.30 exercise price.